On April 1, 2019, 10X Capital Management, LLC announced that it intends to monitor and evaluate its investment in the Galectin Therapeutics, Inc. on a continuing basis. 10X Capital stated that under the terms of the Class B warrants held by 10X Fund, it has the right to nominate 1 person to the board of directors of the Company. 10X Capital stated that it intends to exercise such right, and nominate James C. Czirr for that board position.